SCHEMBL2406795

SCHEMBL2406795

Oc1ccc(Cl)cc1-c1cccc(-c2nnn[nH]2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
MAPT P10636 5/20 0.46
HPGD P15428 4/20 0.46
LMNA P02545 2/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
IDO1 P14902 5/20 0.44
HTT P42858 2/20 0.44
PIM1 P11309 1/20 0.43
PIK3CA P42336 1/20 0.40
RXFP1 Q9HBX9 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALOX5 P09917 1/20 0.37
ALDH1A1 P00352 2/20 0.37
ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2407686 0.87 PIM1 (0.50) MEN1KMT2AMAPTHPGDLMNA
SCHEMBL4339179 0.83 ALOX5 (0.47) MEN1KMT2AMAPTHPGDLMNA
SCHEMBL3363233 0.82 HPGD (0.44) MEN1KMT2AMAPTHPGDLMNA
SCHEMBL704879 0.80 IDO1 (0.54) IDO1SMN1; SMN2TP53ALDH1A1KDM4E
SCHEMBL2410930 0.80 CTSA (0.44) MEN1KMT2AHPGDNPSR1RXFP1
SCHEMBL12761250 0.78 GP6 (0.37) MEN1KMT2AMAPTHPGDLMNA
SCHEMBL1303408 0.76 FGFR2 (0.41)
SCHEMBL4341054 0.76 PIK3CA (0.44) IDO1PIK3CAALOX5ALDH1A1KDM4E
SCHEMBL2405271 0.75 MAPT (0.39) MEN1KMT2AMAPTHPGDLMNA
SCHEMBL5094107 0.75 ALOX5 (0.62) MEN1KMT2AMAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US claimed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP claimed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP claimed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO claimed
US-20150093356-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2015-04-02 US disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
US-20110212054-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC. 2011-09-01 US disclosed
US-7790704-B2 Thrombopoietin mimetics GlaxoSmithKline, LLC (US) 2010-09-07 US disclosed
US-7674887-B2 Thrombopoietin mimetics GLAXOSMITHKLINE LLC (US) 2010-03-09 US disclosed
US-7648971-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. (US) 2010-01-19 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1864981-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-07-22 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070179192-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2007-08-02 US disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-7160870-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-01-09 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MEN1 229/4885KMT2A 1838/4885MAPT 4627/4885
US-20070179192-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MEN1 229/4885KMT2A 1838/4885MAPT 4627/4885
US-20150093356-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MEN1 229/4885KMT2A 1838/4885MAPT 4627/4885
US-20110212054-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MEN1 229/4885KMT2A 1838/4885MAPT 4627/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MEN1 229/4885KMT2A 1838/4885MAPT 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.